River Road Asset Management LLC Increases Holdings in Embecta Corp. $EMBC

River Road Asset Management LLC increased its position in Embecta Corp. (NASDAQ:EMBC) by 5.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,416,401 shares of the company’s stock after acquiring an additional 171,194 shares during the period. River Road Asset Management LLC owned approximately 5.77% of Embecta worth $40,587,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in Embecta by 38.3% in the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock valued at $232,000 after purchasing an additional 5,036 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Embecta by 3.7% during the 1st quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after buying an additional 8,109 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Embecta by 4.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after buying an additional 7,894 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Embecta by 224.0% in the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after buying an additional 91,729 shares in the last quarter. 93.83% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Embecta

Here are the key news stories impacting Embecta this week:

• Negative Sentiment: Multiple law firms, including Rosen Law Firm, Bragar Eagel & Squire, Schall, Robbins, Levi & Korsinsky, and DJS Law Group, announced class actions or investigations related to Embecta, increasing legal overhang and uncertainty for shareholders. Article link
• Negative Sentiment: The lawsuits follow Embecta’s disappointing fiscal second-quarter results released on May 5, including missed EPS and revenue estimates, which are now the focus of the securities-fraud claims. Article link
• Neutral Sentiment: Embecta also named a new senior vice president and president for North America, but this management update appears secondary to the litigation-driven news flow. Article link

Analyst Ratings Changes

Several research firms have weighed in on EMBC. Bank of America dropped their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Weiss Ratings downgraded shares of Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, May 6th. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Mizuho lowered their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Zacks Research downgraded Embecta from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Sell” and a consensus price target of $11.00.

Embecta Stock Up 0.6%

EMBC opened at $3.11 on Friday. The firm has a market cap of $184.52 million, a P/E ratio of 1.64 and a beta of 0.83. The business’s fifty day simple moving average is $5.30 and its 200 day simple moving average is $8.82. Embecta Corp. has a 52 week low of $2.77 and a 52 week high of $15.55.

Embecta (NASDAQ:EMBC) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.15). The firm had revenue of $221.80 million during the quarter, compared to analyst estimates of $235.67 million. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The company’s revenue for the quarter was down 14.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, equities analysts expect that Embecta Corp. will post 1.62 EPS for the current fiscal year.

Embecta Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Thursday, May 28th were given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend was Thursday, May 28th. Embecta’s payout ratio is currently 2.11%.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.